Treatment of chronic HCV infection in special populations

  • Hoefs J
  • Aulakh V
  • 1


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


The mainstay of treatment of chronic hepatitis C is pegylated interferon combined with ribavirin and more than 50% of naïve patients will have viral cure with either 6 months (genotypes 2 and 3) or 12 months (genotypes 1,4, and 6) with the initial treatment. However, populations have been defined that respond less well to routine treatment including African Americans, immune suppressed populations, obese patients and cirrhotic patients. These types of patients are enriched in groups of patients who are non-responders to treatment. This article discusses viral kinetics that may impact treatment response, strategies to maximize treatment effectiveness in these populations and the treatment of non-responders in general. Early viral kinetics can be used to define response or non-response and these results can be used to modify subsequent treatment length and dose. ©2006 Ivyspring International Publisher. All rights reserved.

Author-supplied keywords

  • African American
  • Human immunodeficiency virus infection
  • dose response
  • fatigue
  • fatty liver
  • genotype
  • hepatitis C
  • human
  • immunosuppressive agent
  • kinetics
  • liver cirrhosis
  • liver graft rejection
  • liver transplantation
  • obesity
  • peginterferon alpha2a
  • peginterferon alpha2b
  • postoperative period
  • prevalence
  • review
  • ribavirin
  • treatment response

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • J Hoefs

  • V S Aulakh

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free